Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Pathological analysis of pancreatic neuroendocrine tumors (pNET) is essential for predicting tumor behaviour and patient management. Although endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the established practice for retrieving tissue, fine-needle biopsy (EUS-FNB) offers possibilities for additional analyses including tumor grading. This systematic review provides a comprehensive evaluation of EUS-FNA and EUS-FNB-related adverse events in pNET.
Conference:
Presenting Author: Chen J
Authors: Chen J, Verschuur A, Abdelmonem A, Dreijerink K, Engelsman A,
Keywords: pancreatic neuroendocrine tumor, EUS-FNA, EUS-FNB, adverse events, systematic review,
Introduction: Following resection of primary pancreatic neuroendocrine neoplasm (P-NEN), the reported median disease free survival is ≥4y. 68Ga-DOTATATE PET/CT (DOTA-PET) is widely used for restaging following surgical resection of P-NEN due to a higher sensitivity compared to cross-sectional imaging. We hypothesized that early DOTA-PET has a low yield in detecting recurrent/residual or distant disease in patients following curative-intent surgical resection of non-metastatic localised P-NEN.
Conference:
Presenting Author:
Authors: Singh A, Chan D, Samra J, Pavlakis N, Engel A,
Keywords: Pancreatic NEN, post-resection, restaging, early 68Ga-DOTATATE PET/CT, diagnostic yield,
Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.
Conference:
Presenting Author: Heidsma C
Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,
Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,
Introduction: Pancreatic neuroendocrine tumors (pNET) represent only 6% of pancreatic tumors, compared to 93% for pancreatic ductal adenocarcinoma (PDAC). Textbook outcome (TO) is a composite outcome measure that reflects a hospital’s surgical performance as well as quality of current practice.
Conference:
Presenting Author: Chen J
Authors: Chen J, Augustinus S, Engelsman A, Bonsing B, Groot Koerkamp B,
Keywords: pNET, PDAC, Dutch Pancreatic Cancer Audit, Textbook Outcome, Postoperative results,
Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.
Conference:
Presenting Author: Chen J
Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,
Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,